ANXA2 and glioblastoma: Therefore, a better comprehension of the direct or indirect effects mediated by ANXA2 on ECM degradation, cytoskeletal remodeling and gene transcription, will inevitably lead ANXA2 as future marker to be assessed for GBM management or to be targeted to inhibit dissemination.